This HTML5 document contains 137 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n17http://linked.opendata.cz/resource/AHFS/
n11http://linked.opendata.cz/resource/drugbank/company/
n21http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n24http://linked.opendata.cz/resource/drugbank/drug/DB01173/identifier/chemspider/
n10http://linked.opendata.cz/resource/drugbank/dosage/
n19http://linked.opendata.cz/resource/drugbank/drug/DB01173/identifier/chebi/
n18http://linked.opendata.cz/resource/drugbank/mixture/
n6http://bio2rdf.org/drugbank:
n29http://linked.opendata.cz/resource/drugbank/drug/DB01173/identifier/pharmgkb/
n13http://linked.opendata.cz/resource/drugbank/drug/DB01173/identifier/wikipedia/
admshttp://www.w3.org/ns/adms#
n22http://linked.opendata.cz/resource/drugbank/drug/DB01173/identifier/kegg-compound/
n8http://www.rxlist.com/cgi/generic/
n26http://linked.opendata.cz/resource/drugbank/drug/DB01173/identifier/pubchem-compound/
n23http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n9http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n20http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n27http://linked.opendata.cz/resource/drugbank/drug/DB01173/identifier/pubchem-substance/
n14http://www.drugs.com/cdi/
n25http://linked.opendata.cz/resource/drugbank/drug/DB01173/identifier/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n28http://linked.opendata.cz/resource/drugbank/drug/DB01173/identifier/national-drug-code-directory/
n16http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01173
rdf:type
n3:Drug
n3:description
A muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm. [PubChem]
n3:dosage
n10:271B4E6D-363D-11E5-9242-09173F13E4C5 n10:271B4E6E-363D-11E5-9242-09173F13E4C5 n10:271B4E6B-363D-11E5-9242-09173F13E4C5 n10:271B4E6C-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Ji D, Sui ZY, Ma YY, Luo F, Cui CL, Han JS: NMDA receptor in nucleus accumbens is implicated in morphine withdrawal in rats. Neurochem Res. 2004 Nov;29(11):2113-20. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15662845
n3:group
approved
n3:halfLife
13-20 hours
n3:indication
Indicated for the treatment of Parkinson's disease.
owl:sameAs
n6:DB01173 n23:DB01173
dcterms:title
Orphenadrine
adms:identifier
n13:Orphenadrine n19:7789 n22:C07935 n24:4440 n25:DB01173 n26:4601 n27:46506085 n28:0089-0221-10 n29:PA450715
n3:mechanismOfAction
Orphenadrine binds and inhibits both histamine H1 receptors and NMDA receptors. It restores the motor disturbances induced by neuroleptics, in particular the hyperkinesia. The dopamine deficiency in the striatum increases the stimulating effects of the cholinergic system. This stimulation is counteracted by the anticholinergic effect of orphenadrine. It may have a relaxing effect on skeletal muscle spasms and it has a mood elevating effect.
n3:packager
n11:271B4E38-363D-11E5-9242-09173F13E4C5 n11:271B4E39-363D-11E5-9242-09173F13E4C5 n11:271B4E36-363D-11E5-9242-09173F13E4C5 n11:271B4E37-363D-11E5-9242-09173F13E4C5 n11:271B4E35-363D-11E5-9242-09173F13E4C5 n11:271B4E60-363D-11E5-9242-09173F13E4C5 n11:271B4E56-363D-11E5-9242-09173F13E4C5 n11:271B4E57-363D-11E5-9242-09173F13E4C5 n11:271B4E54-363D-11E5-9242-09173F13E4C5 n11:271B4E55-363D-11E5-9242-09173F13E4C5 n11:271B4E52-363D-11E5-9242-09173F13E4C5 n11:271B4E53-363D-11E5-9242-09173F13E4C5 n11:271B4E50-363D-11E5-9242-09173F13E4C5 n11:271B4E51-363D-11E5-9242-09173F13E4C5 n11:271B4E5E-363D-11E5-9242-09173F13E4C5 n11:271B4E5F-363D-11E5-9242-09173F13E4C5 n11:271B4E5C-363D-11E5-9242-09173F13E4C5 n11:271B4E5D-363D-11E5-9242-09173F13E4C5 n11:271B4E5A-363D-11E5-9242-09173F13E4C5 n11:271B4E5B-363D-11E5-9242-09173F13E4C5 n11:271B4E58-363D-11E5-9242-09173F13E4C5 n11:271B4E59-363D-11E5-9242-09173F13E4C5 n11:271B4E46-363D-11E5-9242-09173F13E4C5 n11:271B4E47-363D-11E5-9242-09173F13E4C5 n11:271B4E44-363D-11E5-9242-09173F13E4C5 n11:271B4E45-363D-11E5-9242-09173F13E4C5 n11:271B4E42-363D-11E5-9242-09173F13E4C5 n11:271B4E43-363D-11E5-9242-09173F13E4C5 n11:271B4E40-363D-11E5-9242-09173F13E4C5 n11:271B4E41-363D-11E5-9242-09173F13E4C5 n11:271B4E4E-363D-11E5-9242-09173F13E4C5 n11:271B4E4F-363D-11E5-9242-09173F13E4C5 n11:271B4E4C-363D-11E5-9242-09173F13E4C5 n11:271B4E4D-363D-11E5-9242-09173F13E4C5 n11:271B4E4A-363D-11E5-9242-09173F13E4C5 n11:271B4E4B-363D-11E5-9242-09173F13E4C5 n11:271B4E48-363D-11E5-9242-09173F13E4C5 n11:271B4E49-363D-11E5-9242-09173F13E4C5 n11:271B4E3E-363D-11E5-9242-09173F13E4C5 n11:271B4E3F-363D-11E5-9242-09173F13E4C5 n11:271B4E3C-363D-11E5-9242-09173F13E4C5 n11:271B4E3D-363D-11E5-9242-09173F13E4C5 n11:271B4E3A-363D-11E5-9242-09173F13E4C5 n11:271B4E3B-363D-11E5-9242-09173F13E4C5 n11:271B4E33-363D-11E5-9242-09173F13E4C5 n11:271B4E34-363D-11E5-9242-09173F13E4C5
n3:synonym
Dimethyl-[2-(phenyl-O-tolyl-methoxy)-ethyl]-amine beta-Dimethylaminoethyl 2-methylbenzhydryl ether Phenyl-O-tolylmethyl dimethyaminoethyl ether N,N-Dimethyl-2-(alpha-2-tolylbenzoyloxy)ethylamine o-monomethyldiphenhydramine 2-(phenyl-o-tolylmethoxy)ethyldimethylamine 2-methyldiphenhydramine β-dimethylaminoethyl 2-methylbenzhydryl ether o-methyldiphenhydramine N,N-Dimethyl-2-[(O-methyl-alpha-phenylbenzyl)oxy]ethylamine Orfenadrina N,N-Dimethyl-2-(phenyl(O-tolyl)methoxy)ethanamine Orphenadrinum ORPHENADRINE
n3:toxicity
Oral, mouse LD<sub>50</sub> = 100 mg/kg; oral, rat LD<sub>50</sub> = 255 mg/kg
n16:hasAHFSCode
n17:12-20-00
n3:foodInteraction
Take without regard to meals. Avoid alcohol.
n3:mixture
n18:271B4E32-363D-11E5-9242-09173F13E4C5 n18:271B4E31-363D-11E5-9242-09173F13E4C5
n3:proteinBinding
95%
n3:salt
n20:hasConcept
n21:M0015454
foaf:page
n8:orphen.htm n14:orphenadrine.html
n3:IUPAC-Name
n4:271B4E73-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4E79-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4E78-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4E75-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4E76-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4E77-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4E88-363D-11E5-9242-09173F13E4C5 n4:271B4E71-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4E8B-363D-11E5-9242-09173F13E4C5 n4:271B4E72-363D-11E5-9242-09173F13E4C5 n4:271B4E6F-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4E70-363D-11E5-9242-09173F13E4C5
n3:pKa
n4:271B4E8C-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B4E7F-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4E80-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4E7A-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4E7B-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4E7D-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4E7C-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4E7E-363D-11E5-9242-09173F13E4C5
n3:absorption
Orphenadrine is almost completely absorbed in the gastrointestinal tract.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
83-98-7
n3:category
n3:containedIn
n9:271B4E69-363D-11E5-9242-09173F13E4C5 n9:271B4E6A-363D-11E5-9242-09173F13E4C5 n9:271B4E67-363D-11E5-9242-09173F13E4C5 n9:271B4E68-363D-11E5-9242-09173F13E4C5 n9:271B4E65-363D-11E5-9242-09173F13E4C5 n9:271B4E66-363D-11E5-9242-09173F13E4C5 n9:271B4E63-363D-11E5-9242-09173F13E4C5 n9:271B4E64-363D-11E5-9242-09173F13E4C5 n9:271B4E61-363D-11E5-9242-09173F13E4C5 n9:271B4E62-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B4E84-363D-11E5-9242-09173F13E4C5
n3:Boiling-Point
n4:271B4E8A-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4E86-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4E87-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B4E89-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4E83-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4E82-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4E85-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4E74-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4E81-363D-11E5-9242-09173F13E4C5